Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man

Stem Cells

Volumn 17, Issue 4, 1999, Pages 203-209

  De Serres, Mark ^a   Ellis, Byron ^a   Dillberger, John E ^a   Rudolph, Sharon K ^a   Hutchins, Jeff T ^a   Boytos, Christine M ^a   Weigl, Debra L ^a   DePrince, Randolph B ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

GW395058; Immunogenicity; Mice; Mimetic peptide; Neutralizing antibody; Rabbits; Thrombopoietin

Indexed keywords

AF 15705; GW 395058; NEUTRALIZING ANTIBODY; RECEPTOR PROTEIN; RECOMBINANT THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL HYPERPLASIA; CONTROLLED STUDY; CROSS REACTION; IMMUNOGENICITY; IMMUNOSTIMULATION; MALE; MEGAKARYOPOIESIS; NONHUMAN; RECEPTOR BINDING; THROMBOCYTOPENIA;

ORYCTOLAGUS CUNICULUS;

EID: 0032797771     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.170203     Document Type: Article

References (35)

1. Kudoh S, Yamada M. [Cytokine in cancer chemotherapy - clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia]. Gan To Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1998;25:171-176.
2. Isaacs C, Robert NJ, Bailey FA et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thiombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368-3377.
3. Tepler I, Elias L, Smith JW 2nd et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-3614.
4. Kaushansky K. Thrombopoietin: the primary regulator of platelet production (Comments). Blood 1995;86:419-431.
5. Kato T, Ogami K, Shimada Y et al. Purification and characterization of thrombopoietin [published erratum appears in J Biochem (Tokyo) 1996;119:208]. J Biochem 1995;118:229-236.
6. Harker LA, Hunt P, Marzec UM et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996;87:1833-1844a.
7. Kabaya K, Akahori H, Shibuya K et al. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells 1996;14:651-660.
8. Akahori H, Shibuya K, Ozai M et al. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells 1996;14:678-689.
9. Akahori H, Shibuya K, Obuchi M et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996;94:722-728.
10. Shibuya K, Akahori H, Takahashi K et al. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998;91:37-45.
11. Andrews RG, Winkler A, Myerson D et al. Recombinant human ligand for MPL. megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. Stem Cells 1996;14:661-677.
12. Molineux G, Hartley CA, McElroy P et al. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996;88:1509-1514.
13. Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-521.
14. Harker LA, Marzec UM, Kelly AB et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood 1997;89:155-165.
15. Vadhan-Raj S, Murray LJ, Bueso-Ramos C et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer (Comments). Ann Intern Med 1997;126:673-681.
16. Geissler K, Kabrna E, Stengg S et al. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. Br J Haematol 1998;102:535-543.
17. Basser RL, Rasko JE, Clarke K et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer [published erratum appears in Blood 1997;90:2513]. Blood 1997;89:3118-3128.
18. Rasko JE, Basser RL, Boyd J et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 1997;97:871-880.
19. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998;43:148-151.
20. PJB Publications Ltd. Amgen Halts Growth Factor Trials. Scrip 1998;2370:20.
21. Cwirla SE, Balasubramanian P, Duffin DJ et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-1699.
22. Singer SC, Tansik RL, Dev IK et al. Pegylated thrombopoi-etin (TPO)-mimetic peptides bind human TPO receptor causing proliferation and maturation of megakaryocytes. Blood 1998;92:568a.
23. Boytos CM, Rudolph SK, Merrell C et al. Pegylated thrombopoietin-mimetic peptides elevate blood platelets and ablate the chemotherapy-induced platelet nadir in mice. Blood 1998;92:377a.
24. de Serres M, Hutchins J, Ellis B et al. Immunogenicity studies of the thrombopoietin mimetic peptide GW395058 in BALB/c mice, New Zealand white rabbits, and cynomolgus monkey. Blood 1998;92:173.
25. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem 1995;6:150-165.
26. Francis GE, Delgado C, Fisher D. PEG-modified proteins. In: Ahern TJ, Manning MC, eds. Stability of Protein Pharmaceuticals, Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilization, vol. 2. New York: Plenum Press, 1992:235-263.
27. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1988.
28. Fagerstam LG, Frostell A, Karlsson R et al. Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. J Mol Recognit 1990;3:208-214.
29. Fagerstam LG, Frostell-Karlsson A, Karlsson R et al. Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. J Chromatogr 1992;597:397-410.
30. Sheehan DC, Hrapchak BB. Theory and Practice of Histotechnology. Columbus: Battelle Press, 1980.
31. Carson FL. Histotechnology, A Self-Instructional Text. Chicago: American Society of Clinical Pathologists, 1997.
32. Abuchowski A, McCoy JR, Palczuk NC et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-3586a.
33. Abuchowski A, van Es T, Palczuk NC et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;252:3578-3581.
34. Saifer MG, Somack R, Williams LD. Plasma clearance and immunologic properties of long-acting Superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol. Adv Exp Med Biol 1994;366:377-387.
35. Clark R, Olson K, Fuh G et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271:21969-21977.